PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Cannabinoid company expands into oncology

OCTP develops cannabinoid medicines and is looking at the potential treatment of cancer malignancies.

Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it identified a potential first-in-class immunotherapy agent for solid tumour treatment.

Indeed, initial data suggests substantive potential for the development of a cannabinoid-based therapy that could be used at home, in tablet form.

OCTP’s analysis of the initial data shows sound drug-like potential in terms of in vitro potency and selectivity to target, as well as in vivo availability within blood.

The also company believes it could be a less harmful alternative to existing therapies while chiming with growing public recognition of cannabinoid-based medicines as a viable treatment for a range of conditions.

The candidate has arisen from the work being carried out on OCTP’s cannabinoid library of almost 500 derivatives for the company’s ‘Programme 4’ research. At this stage of development, OCTP believes the potency shown on the selected target in vitro – in addition to its in vivo behaviour – demonstrates considerable potential.

Clarissa Sowemimo-Coker, chief executive officer of OCTP, was optimistic about the latest results: “There is an urgent need for new cancer medications. The OCTP team has discovered a potential first-line-treatment alternative to existing therapies and their side effects which could provide a viable alternative to expensive biologics.”

“Although we’re at an early stage, this is exciting news for the company. As the potential of cannabinoid-based medicines to treat a range of conditions in a less harmful and more economical manner receives growing public recognition, OCTP stands at the forefront of research and development and we are extremely excited to have identified a possible candidate that could have a significant impact on many people’s lives,” she added.

She concluded: “We are innovative specialists within the global pain and oncology markets and we will continue to develop new opportunities that will ultimately benefit people suffering from a range of debilitating, life-altering conditions.”

Attention will now move to further in vitro and in vivo studies and will, ultimately, be followed by a safety-pharmacology assessment before final candidate selection during 2024.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026